Skip to content

DNLI - Denali Therapeutics Inc. - AlphaYou

Discover Compare Pricing

Sign in Sign up

Home Smart money Buy calls Analyze

Back to stock searchD

Denali Therapeutics Inc

DNLI · NASDAQ

Save to watchlist

Price is syncing

Reported smart-money activity for this stock is still below.

D

DNLIDenali Therapeutics Inc

Overview

No source-backed view yet. This page is available for price, fundamentals, and future receipts as coverage warms.

Key stats

Aug 20

52-wk high: $27.30
52-wk low: $12.58
Prev close: $22.31
Mkt cap: $4.11B
Beta: 1.00
P/S: 1139.4x

Smart money

8 funds hold a position.

Real smart money

Funds holding this stock

8 holders

Combined position$1.1B

MI
Millennium
Israel Englander · Q2 2026 13F
$29.0M
position
P7
Point72
Steven Cohen · Q4 2025 13F

Earnings

Reported Aug 6, 2026

Earnings came in 5.6% above what analysts expected.

Documents

Quarterly report10-Q Annual report10-K

Financials

Fundamentals

Is the business strong?

This company is running thin margins.

Net margin: 0.0%
Market cap: $4.1B

Valuation

P/S1139.42
P/B4.66

Quality

Operating margin-3601.0%
ROE

Technicals

Technicals

Price structure

No data yet

Technicals sync when verified market data is available. No sample data is shown.

Company

Symbol: DNLI
Exchange: NASDAQ
Sector: HEALTHCARE
Industry: BIOTECHNOLOGY
Market cap: $4.11B
Beta: 1.00

Analysts

What do analysts expect?

Analyst target and ratings are on paid plans

See the 12-month consensus target and the buy/hold/sell rating split.

Unlock the full results

Research hubs
About
Editorial policy
Methodology
Source coverage
Corrections

Privacy
Terms
Refunds
Disclaimer

© 2026 AlphaYou. All rights reserved.Not financial advice. Do your own research. Informational data only; past performance does not predict future results.

P/B

4.7x

Profit margin

+0.0%

Op margin

-3601.0%

ROE

-54.9%

$28.1M

position

MW

Marshall Wace

Q2 2026 13F

$14.1M

position

5 more holders

Lite opens all of them for $16.50/month, paid yearly.

Unlock all 5 holders

Coverage gaps for DNLI

No recent insider trade
No recent Congress trade
No recent market-voice mention

Earnings per share

-$0.68+5.6%

-$0.72 expected

Next report

What the street expects next

EPS expected

-$0.41

-$0.88 to $0.37

Revenue expected

$23.5M

17 analysts

Last 30 days

1up3down

Analysts cutting estimates

Estimate drift

+0.13

Change in 30 days

-54.9%

ROA-29.1%

Growth

Beta1.00